About

About HKUBio - Hong Kong Universal Biologicals Company Limited Hong Kong Universal Biologicals Company Limited (HKUBio) is a Hong Kong -based biotech R&D Company, spinoff from The University of Hong Kong (HKU), Centre for Virology, Vaccinology and Therapeutics (CVVT) (InnoHK@HKUMed), and in collaboration with The State Key Laboratory for Emerging Infectious Diseases (SKLEID) of the Department of Microbiology at the University of Hong Kong. We set up at the Hong Kong Science Park in developing innovative vaccine products, possesses the Viral Vector Vaccines Technology system (DelNS1), along with a series of patents for developing intranasal vaccines for respiratory viruses. This technology platform is based on a flu-based viral vector and can be utilized for creating vaccines for flu, COVID-19, and other respiratory viral diseases. The first intranasal spray vaccine for COVID-19 developed using this technology platform has been approved for human use in mainland China in 2022. One of the unique advantages of this vaccine system is its ability to combine vaccines for flu and other respiratory viral infections, inducing both systemic and mucosal immunity, a feat not achievable by other intramuscularly injected vaccines. This platform technology was awarded the Gold Medal with Congratulations of the Jury" the Special Edition 2021 Inventions Geneva Evaluation Days The platform of the DelNS1 vaccine system technology has been utilized to generate vaccines for seasonal influenza, COVID-19, Flu-COVID (a combination vaccine for flu and COVID-19 in a single composition), Flu-RSV (a combination vaccine for flu and RSV in a single composition), and Flu-hMPV (a combination vaccine for flu and hMPV in a single composition). Our showcase will highlight the technology and the development of vaccine candidates for a variety of common cold viruses. The DelNS1-RBD vaccine for COVID-19 based on this technology has successfully completed all phases of clinical trials and has received approval for human use in China in 2022. Development is underway for vaccines targeting influenza and RSV, with plans to enter investigational new drug (IND) status within one to two years. Additionally, a vaccine candidate for the potential emerging H5N1 virus has been created and will undergo evaluation in humans to facilitate technology stockpiling for pandemic preparedness. Concurrently, a series of vaccines for common cold viruses are in development and are slated for human evaluation within the next 3-5 years through collaborative efforts with other partners. This technology focuses on Life and Health Technology R&D. Given the impact of the COVID-19 pandemic and the efficient transmission of SARS-CoV-2, The development of effective vaccines that can induce both systemic and mucosal immunity is considered to be the focus of the next generation of vaccines for respiratory viruses. The technology showcased here is exceptionally innovative as it can be integrated with flu vaccines to target other respiratory viral infections. Its practicality is underscored by successful human trials and the approval of a product based on this technology for human use.